Literature DB >> 6454386

Moxalactam pharmacokinetics during hemodialysis.

G R Aronoff, R S Sloan, S A Mong, F C Luft, S A Kleit.   

Abstract

To establish dosage recommendations, moxalactam elimination kinetics were studied in six anephric patients during hemodialysis and in four anephric patients during the interdialytic period. After a single 1-g intravenous bolus injection, moxalactam elimination half-life was 18.0 plus or minus 0.6 h with a volume of distribution of 20.2 plus or minus 3.6 liters and a plasma clearance of 12.8 plus or minus 2.0 ml/min in four nondialyzed patients. Moxalactam elimination half-life was decreased to 2.7 plus or minus 0.2 h during hemodialysis in six patients. After 4 h, 48.5% of the dose was recovered in the dialysate. The maintenance dose of moxalactam should be decreased to 15% of a normal dose in patients with creatinine clearances less than 10 ml/min, and 50% of a loading dose should be given after hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6454386      PMCID: PMC181480          DOI: 10.1128/AAC.19.4.575

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers.

Authors:  J N Parsons; J M Romano; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

3.  Artificial kidneys and clearance calculations.

Authors:  T P Gibson; E Matusik; L D Nelson; W A Briggs
Journal:  Clin Pharmacol Ther       Date:  1976-12       Impact factor: 6.875

4.  Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria.

Authors:  M V Borobio; J Aznar; R Jimenez; F Garcia; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

5.  Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.

Authors:  R N Jones; P C Fuchs; H M Sommers; T L Gavan; A L Barry; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

6.  Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol.

Authors:  C S Lee; T C Marbury; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1980-02
  6 in total
  9 in total

1.  Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administration.

Authors:  T E Jones; R W Milne; Y Mudaliar; L N Sansom
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  Pharmacokinetics of moxalactam in elderly subjects.

Authors:  M H Andritz; R P Smith; A L Baltch; P E Griffin; J V Conroy; N Sutphen; M C Hammer
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

4.  High performance liquid chromatographic determination of moxalactam in human plasma and cerebrospinal fluid.

Authors:  J Nielsen; G Karlaganis; H M von Hattingberg; U B Schaad
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 6.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

7.  Moxalactam pharmacokinetics in children.

Authors:  M F Romagnoli; K Flynn; G R Siber; D A Goldmann
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

8.  Pharmacokinetics, protein binding, and predicted extravascular distribution of moxalactam in normal and renal failure subjects.

Authors:  L R Peterson; B Bean; C E Fasching; W P Korchik; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

9.  In vitro activity, efficacy, and pharmacology of moxalactam, a new beta-lactam antibiotic.

Authors:  R Snepar; G Poporad; J Romano; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.